سعر سيمفاستيميب 10/40مجم 30 اقراص 2021

Simvastimibe 10/40 mg tablets (ezetimibe 10 mg + simvastatin 40 mg), pack of 30, by Eva Pharma; a fixed-dose combination of a cholesterol absorption inhibitor and a statin.

• Adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia.Population: AdultsDailyMed (U.S. National Library of Medicine)
• Adjunct to diet to reduce elevated LDL-C in adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia.Population: Adults and pediatric patients 10 years and olderDailyMed (U.S. National Library of Medicine)
• Adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Adverse reactions in ≥2% of patients and more often than placebo: headache, upper respiratory tract infection, myalgia, diarrhea, pain in extremity and influenza.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Concomitant use of strong CYP3A4 inhibitors (select azole antifungals, macrolide antibiotics, antivirals, nefazodone).International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Concomitant use of cyclosporine, danazol or gemfibrozil.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Acute liver failure or decompensated cirrhosis.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Myopathy and rhabdomyolysis: risk factors include age 65 or older, uncontrolled hypothyroidism, renal impairment, certain concomitant drugs and higher dosage; Chinese patients may be at higher risk; discontinue if CK is markedly elevated or myopathy is diagnosed or suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Immune-mediated necrotizing myopathy has been reported; discontinue if suspected.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Hepatic dysfunction: consider liver enzyme testing before initiation and when clinically indicated; interrupt if serious hepatic injury occurs.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inhibitors, cyclosporine, danazol, gemfibrozilIncreased simvastatin exposure and risk of myopathy/rhabdomyolysis; concomitant use contraindicated.DailyMed (U.S. National Library of Medicine)
• Verapamil, diltiazem, dronedaroneDo not exceed 10/10 mg once daily (this 10/40 mg tablet exceeds that limit).DailyMed (U.S. National Library of Medicine)
• Amiodarone, amlodipine, ranolazineDo not exceed 10/20 mg once daily (this 10/40 mg tablet exceeds that limit).DailyMed (U.S. National Library of Medicine)

• Discontinue when pregnancy is recognized; may cause fetal harm based on the mechanism of action. Alternatively, consider the ongoing therapeutic needs of the individual patient.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Breastfeeding is not recommended during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Ezetimibe: Inhibits intestinal absorption of cholesterol and related phytosterols.
• Simvastatin: Inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis.